SynAct Pharma AB (SYNACT) — Working Capital to Net Assets Ratio
SynAct Pharma AB (SYNACT) has a Working Capital to Net Assets ratio of 36.4% as of March 2026. Working capital of Skr70.62 Million (current assets of Skr85.53 Million minus current liabilities of Skr14.91 Million) is measured against net assets of Skr193.75 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See SynAct Pharma AB financial flexibility index to measure the company's free cash flow as a share of total liabilities.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
SynAct Pharma AB Working Capital to Net Assets (2014–2025)
This chart shows how SynAct Pharma AB's Working Capital to Net Assets ratio has evolved across 12 annual periods from 2014 to 2025. As of March 2026, the ratio stands at 36.4%, reflecting working capital of Skr70.62 Million against net assets of Skr193.75 Million SEK. See SYNACT days of operational coverage to measure how many days the company can operate on defensive assets alone.
Annual Working Capital to Net Assets for SynAct Pharma AB (2014–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for SynAct Pharma AB from 2014 to 2025, covering 12 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see SynAct Pharma AB market capitalisation.
| Year | WC/NA Ratio | Working Capital (SEK) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 29.3% | Skr49.82 Million | Skr170.29 Million | Skr71.35 Million | Skr21.52 Million | ▼ -1.3 pp |
| 2024 | 30.6% | Skr65.54 Million | Skr214.17 Million | Skr94.00 Million | Skr28.46 Million | ▲ +2.2 pp |
| 2023 | 28.4% | Skr50.12 Million | Skr176.19 Million | Skr75.06 Million | Skr24.94 Million | ▼ -70.5 pp |
| 2022 | 99.0% | Skr125.22 Million | Skr126.52 Million | Skr140.23 Million | Skr15.01 Million | ▲ +5.4 pp |
| 2021 | 93.6% | Skr19.53 Million | Skr20.87 Million | Skr34.92 Million | Skr15.39 Million | ▼ -4.8 pp |
| 2020 | 98.3% | Skr15.60 Million | Skr15.87 Million | Skr21.33 Million | Skr5.72 Million | ▲ +112.1 pp |
| 2019 | -13.8% | Skr-1.86 Million | Skr13.50 Million | Skr8.45 Million | Skr10.31 Million | ▼ -105.1 pp |
| 2018 | 91.3% | Skr9.42 Million | Skr10.31 Million | Skr13.14 Million | Skr3.72 Million | ▲ +0.2 pp |
| 2017 | 91.1% | Skr11.76 Million | Skr12.91 Million | Skr14.08 Million | Skr2.31 Million | ▼ -4.9 pp |
| 2016 | 96.0% | Skr25.99 Million | Skr27.08 Million | Skr29.48 Million | Skr3.49 Million | ▲ +87.9 pp |
| 2015 | 8.1% | Skr26.00K | Skr320.00K | Skr83.00K | Skr57.00K | ▼ -31.3 pp |
| 2014 | 39.4% | Skr253.00K | Skr642.00K | Skr334.00K | Skr81.00K | — |